Effectiveness of Canakinumab for First‐Line Steroid‐Free Treatment in Systemic‐Onset Juvenile Idiopathic Arthritis and Juvenile Still Disease

Documenti analoghi

• Characteristics That Predict Psoriatic Arthritis by the Classification Criteria for Psoriatic Arthritis in Patients With Juvenile Idiopathic Arthritis 18 Years After Disease Onset
  di: Agnes Szentpetery, et al.
  Pubblicazione: (2024)
• Transarterial Embolization for Refractory Ankle Synovitis in an Adult Patient With a History of Juvenile Idiopathic Arthritis
  di: Francesco Ursini, et al.
  Pubblicazione: (2025)
• Associations of Lymphocyte Subpopulations, Related Cytokines, Clinical Phenotypes, and Outcomes in Systemic Juvenile Idiopathic Arthritis
  di: Butsabong Lerkvaleekul, et al.
  Pubblicazione: (2025)
• Predictors of Disease Activity in Patients With Juvenile Idiopathic Arthritis at 12 and 24 Months After Diagnosis
  di: Erin Balay‐Dustrude, et al.
  Pubblicazione: (2024)
• Reliability and Construct Validity of the Physician's Global Assessment of Lung Disease in Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease
  di: Eileen Rife, et al.
  Pubblicazione: (2026)